Obagi Medical has launched a large‑scale, practice‑driven clinical initiative designed to gather real‑world evidence on its first FDA‑approved hyaluronic acid filler, Obagi saypha MagIQ, in collaboration with leading med spa and dermatology platforms nationwide. The ALOHA Program reflects a growing industry focus on real‑world data, integrated skincare and injectable protocols, and practice‑led insights that can directly inform clinical education and business outcomes for medical spas.

Unveiled in January 2026, the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program is designed to become the largest real‑world evaluation of a newly launched hyaluronic acid (HA) filler to date. Rather than relying solely on traditional clinical trial data, the program embeds Obagi saypha MagIQ into routine patient care across a wide range of real‑world practice environments. Participating practices provide structured, standardized feedback from injectors and practice owners, capturing insights that extend beyond controlled trial settings. 

According to Obagi Medical, the program is intended to bridge the gap between FDA trials and everyday clinical practice, where factors such as injector technique, patient demographics, and workflow efficiency play a critical role in outcomes. The resulting data will inform post‑launch education, scientific content, and broader adoption strategies across the aesthetic industry.

“ALOHA reflects our commitment to launching innovation differently and supporting category growth,” said Drew Fine, U.S. General Manager, Professional Channel. “By gathering real-world data across diverse practice settings, we will demonstrate how Obagi saypha MagIQ and Obagi skincare can drive practice success and patient satisfaction. The program's inclusive design embodies our Aesthetics for All ethos and invites broad industry participation.”

Obagi saypha MagIQ is Obagi Medical’s first FDA‑approved injectable HA filler and was developed by Croma‑Pharma GmbH using proprietary MACRO Core Technology. The filler is designed to deliver high usable HA content at injection, consistent gel distribution, and predictable injection force and swelling profiles. 

Strategic partnerships

Obagi Medical has announced multiple high‑profile collaborations under the ALOHA umbrella.

In late January, Alpha Aesthetic Partners was named a launch partner, conducting a structured, multi‑site evaluation of Obagi saypha MagIQ across its growing national network of medical aesthetic practices. Alpha was selected for its emphasis on standardized training, cross‑practice collaboration, and patient satisfaction metrics.

“At Alpha, we’re focused on building capabilities and partnerships that meaningfully support our practices,” said John Wheeler, CEO of Alpha Aesthetics Partners. “What stood out about Obagi’s approach was the emphasis on real-world data and a thoughtful look at how skincare and injectables can work together to drive better outcomes for patients and providers.”

Obagi Medical also announced VIO Med Spa as an ALOHA launch partner, leveraging the franchise’s multi‑location footprint and high‑volume aesthetic treatment model. VIO Med Spa will conduct a structured assessment of the filler across its locations, with standardized data collection focused on both clinical performance and patient experience. 

“At VIO Med Spa, we’re committed to elevating aesthetic medicine through clinical excellence, innovation, and exceptional patient outcomes,” said Dr. Alan Durkin, Chief Medical Officer of VIO Med Spa. “Obagi’s ALOHA Program perfectly aligns with our mission by emphasizing real-world data and integrated skincare-injectable protocols. This partnership allows us to contribute meaningful insights that enhance results for our patients and advance the industry as a whole.”

For more information about ALOHA, visit https://obagi-professional.com. Safety information about Obagi Medical is available on the brand's website, https://www.obagi.com.